Shared Control: Novel Trial Design Works In COVID, But Will Sponsors Buy In?
Executive Summary
COVID-19 has helped demonstrate the viability of platform trials with a shared control arm. That model is easier to extol than it is for sponsors to embrace, especially outside of crisis mode.
You may also be interested in...
How The EU Is Keeping Up With Innovation In Clinical Trials
A senior EMA official says Europe has set the ball rolling on presenting a unified approach on clinical trial processes and strategic matters, and is taking steps to ensure there are no roadblocks.
Real-Word Evidence Generation System Will Be A Priority For Califf As FDA Commissioner
At his Senate confirmation hearing, Robert Califf said he wants to establish a system, built on electronic medical records, that can be used to more quickly confirm the benefits and risks of accelerated approval drugs.
Better Late Than Never? US FDA’s Oddly Timed COVID Master Protocol Guidance
COVID has unequivocally shown the advantages of a ‘master protocol’ approach to providing definitive evidence about the benefits (or lack thereof) for repurposed therapies to treat a novel infection. Unfortunately, in the US, the proof has been in the failure of scores of separate studies to generate useful evidence. Can FDA change that before the next pandemic?